BioSpace News Archive

Specialty cancer diagnostics company Precipio, Inc., will be hosting its Q2-2023 corporate update call on August 17th at 5:00 PM ET.

Crinetics Pharmaceuticals, Inc. announced that on August 10, 2023, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 150,600 shares of its common stock to seven new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan.

Akebia Therapeutics®, Inc. announced that it has filed with the U.S. Securities and Exchange Commission a Form 12b-25 Notification of Late Filing with regard to its Quarterly Report on Form 10Q for the quarter ended June 30, 2023.

Extendicare Inc. reported results for the three and six months ended June 30, 2023.

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in China in the pivotal Phase III registration study of TLX591-CDx (Illuccix®, Kit for the preparation of 68Ga-PSMA-11),[1] for the imaging of prostate cancer using positron emission tomography (PET).

Vivos Therapeutics, Inc. announced it plans to release its second quarter 2023 financial results after market close on Monday, August 14, 2023.

BMI Korea Co., LTD. (“BMI Korea”), a leading Korean biotech company specializing in biologics development, introduces its novel recombinant hyaluronidase, BMI-2004, and shares Phase 1 clinical trial results at the 15th Annual Bioprocessing Summit being held in Boston (August 14-17th, 2023).

MDxHealth SA, a commercial-stage precision diagnostics company, announced it will release its financial results for the second quarter and half year ended June 30, 2023, after market close on Wednesday, August 23, 2023.

Erasca, Inc., a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, reported financial results for the fiscal quarter ended June 30, 2023, and provided business updates.

Tarsus Pharmaceuticals, Inc. announced financial results for the second quarter ended June 30, 2023, and recent business achievements.